Inovio Pharmaceuticals
118 hedge funds and large institutions have $176M invested in Inovio Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
69% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $1.52M
32% more capital invested
Capital invested by funds: $133M → $176M (+$43M)
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
11% more funds holding
Funds holding: 106 → 118 (+12)
0.26% more ownership
Funds ownership: 2.25% → 2.5% (+0.26%)
Top Buyers
| 1 |
Millennium Management
New York
|
+$5.73M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.65M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.58M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.28M |
| 5 |
Morgan Stanley
New York
|
+$1.14M |
Top Sellers
INO Hedge Fund Activity: Q2 2017 in Review
118 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2017, worth a combined $176M — up 32% from $133M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new INO positions and 9 closed out — a net gain of 13 holders — while 33 added to existing stakes and 25 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.73M. The largest seller was State Street, cutting an estimated $2.38M.
- 118 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2017, up from 106 in Q1 2017.
- Funds reported $176M of Inovio Pharmaceuticals stock for Q2 2017, up 32% quarter-over-quarter.
- 22 funds opened new Inovio Pharmaceuticals positions in Q2 2017 and 9 closed out, a net change of +13 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2017 was Millennium Management, an estimated $5.73M added.
- The largest Inovio Pharmaceuticals seller in Q2 2017 was State Street, an estimated $2.38M sold.
Based on aggregated 13F filings for Q2 2017.